112257-24-6

Basic information

• Product Name: 4-Boc-2-piperazinecarboxamide
• Synonyms: 4-Boc-2-piperazinecarboxamide;Tert-butyl3-carbamoylpiperazine-1-carboxylate;1-Boc-3-carbaMoylpiperazine;1-Piperazinecarboxylic acid, 3-(aMinocarbonyl)-, 1,1-diMethylethyl ester;3-Carbamoyl-piperazine-1-carboxylic acid tert-butyl ester;4-(tert-Butoxycarbonyl)piperazine-2-carboxamide;tert-Butyl 3-aminocarbonyl-1-piperazinecarboxylate
• CAS NO: 112257-24-6
• Molecular Formula: C₁₀H₁₉N₃O₃
• Molecular Weight: 229.28
• Product Categories: pharmacetical
• Mol File: 112257-24-6.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 404.3°Cat760mmHg
• Flash Point: 198.3°C
• Appearance: /
• Density: 1.151g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.497
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 4-Boc-2-piperazinecarboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Boc-2-piperazinecarboxamide(112257-24-6)
• EPA Substance Registry System: 4-Boc-2-piperazinecarboxamide(112257-24-6)

Safety Data

• Hazardous Substances Data: 112257-24-6(Hazardous Substances Data)

Usage

General Description

4-Boc-2-piperazinecarboxamide is a chemical compound with the molecular formula C12H21N3O3. It is a derivative of piperazine and contains a tert-butoxycarbonyl (Boc) protecting group on the nitrogen atom. 4-Boc-2-piperazinecarboxamide is commonly used as an intermediate in organic synthesis and is often employed in the preparation of pharmaceutical drugs. It has been studied for its potential use in the treatment of various medical conditions, including central nervous system disorders and cancer. 4-Boc-2-piperazinecarboxamide is a versatile chemical with multiple potential applications in the pharmaceutical industry.

InChI:InChI=1/C10H19N3O3/c1-10(2,3)16-9(15)13-5-4-12-7(6-13)8(11)14/h7,12H,4-6H2,1-3H3,(H2,11,14)

Upstream product

• 126937-41-5 1-(benzyloxycarbonyl)-4-(tert-butoxycarbonyl)-2-piperazinecarboxylic acid 
• 67-56-1 methanol 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 129799-08-2 tert-butyl methyl piperazine-1,3-dicarboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 84501-64-4 2-aminocarbonylpiperazine 

Downstream Products

• 955016-61-2 1-benzyl 4-tert-butyl 3-(aminocarbonyl)piperazine-1,4-dicarboxylate 
• 159484-66-9 N-(2,6-dimethylphenyl)-4-formyl-1-piperazineacetamide 
• 166520-14-5 3S-(-)-1,1-dimethylethyl 3-aminocarbonyl-4-<<<(4-nitro-2,6-dichlorophenyl)amino>carbonyl>methyl>-1-piperazinecarboxylate 
• 166520-13-4 3R-(+)-1,1-dimethylethyl 3-aminocarbonyl-4-<<<(4-nitro-2,6-dichlorophenyl)amino>carbonyl>methyl>-1-piperazinecarboxylate 
• 170164-47-3 3S-(+)-1,1-dimethylethyl 3-aminocarbonyl-1-piperazinecarboxylate 
• 166520-16-7 2S-(-)-1,1-dimethylethyl 3-aminocarbonyl-4-<<<(4-amino-2,6-dichlorophenyl)amino>carbonyl>methyl>-1-piperazinecarboxylate 
• 159572-93-7 (S)-(-)-Piperazine-2-carboxamide 

Relevant articles and documents

Aromatic heterocyclic derivatives and applications of aromatic heterocyclic derivatives in medicines

The present invention discloses aromatic heterocyclic derivatives and applications of the aromatic heterocyclic derivatives in medicines, and specifically provides a class of aromatic heterocyclic compounds or stereoisomers, geometric isomers, tautomers, racemic bodies, nitrogen oxides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof, and pharmaceutical compositions containing the compounds. The present invention further discloses uses of the compounds or pharmaceutical compositions in drug preparation, wherein the drug is used for treatment of respiratory diseases, particularly chronic obstructive pulmonary disease (COPD).

COVALENT INHIBITORS OF KRAS G12C

Irreversible inhibitors of G12C mutant K-Ras protein are provided. Also disclosed are methods to modulate the activity of G12C mutant K-Ras protein and methods of treatment of disorders mediated by G12C mutant K-Ras protein.

QUINAZOLINE DERIVATIVES

The invention concerns quinazoline derivatives of Formula (I) wherein each of R1, R3, R20, X1, X2, Z, W, (a) and (q) have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of turnours which are sensitive to inhibition of erbB receptor tyrosine kinases, particularly EGFR tyrosine kinase.